Supplier Review
Reviewed March 17, 2026
Is CPC Scientific legit?
CPC Scientific presents differently from a direct-to-catalog research seller. As of March 17,
2026, it publicly positions itself as a peptide and oligo CRDMO with GMP manufacturing,
late-phase development support, and U.S. expansion tied to peptide API capacity. That can
indicate a more institutional operating model, but a buyer should still verify the exact site,
program scope, and regulatory relevance for the material being sourced.
Public claims reviewed
- CRDMO focus for peptides and oligonucleotides.
- GMP manufacturing and late-phase/commercial production positioning.
- Hangzhou manufacturing history and U.S. Rocklin expansion narrative.
- Public references to prior FDA inspection outcomes and current capacity expansion.
Source pages reviewed March 17, 2026: Homepage,
Company profile,
FDA inspection post,
California facility post.
What a buyer should verify
- Which site would actually manufacture your program and under what quality system.
- Whether the public inspection history is directly relevant to your intended material and process.
- Whether quoted scope is development support, GMP API manufacture, or something narrower.
- Whether capacity and timeline claims align with your batch size and program phase.
Why buyers still screen established CDMOs
- Because a credible company can still be the wrong fit for a specific peptide, timeline, or budget.
- Because “GMP capable” is different from “best option for this procurement decision.”
- Because the right diligence question is often scope fit, not just legitimacy.
APV view
CPC Scientific looks like a more formal CRDMO profile than many catalog-oriented sellers,
but buyers still need program-level verification: site relevance, documentation fit, and
manufacturing scope for the exact work being quoted.